Filtered By:
Source: The Lancet Neurology
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 249 results found since Jan 2013.
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial
Publication date: Available online 23 February 2017 Source:The Lancet Neurology Author(s): Pierre Amarenco, Gregory W Albers, Hans Denison, J Donald Easton, Scott R Evans, Peter Held, Michael D Hill, Jenny Jonasson, Scott E Kasner, Per Ladenvall, Kazuo Minematsu, Carlos A Molina, Yongjun Wang, K S Lawrence Wong, S Claiborne Johnston Background Ticagrelor is an effective antiplatelet therapy for patients with coronary atherosclerotic disease and might be more effective than aspirin in preventing recurrent stroke and cardiovascular events in patients with acute cerebral ischaemia of atherosclerotic origin. Our aim was to te...
Source: The Lancet Neurology - February 23, 2017 Category: Neurology Source Type: research
Sex differences in the evaluation and treatment of acute ischaemic stroke
Publication date: July 2018 Source:The Lancet Neurology, Volume 17, Issue 7 Author(s): Cheryl Bushnell, Virginia J Howard, Lynda Lisabeth, Valeria Caso, Seana Gall, Dawn Kleindorfer, Seemant Chaturvedi, Tracy E Madsen, Stacie L Demel, Seung-Jae Lee, Mathew Reeves With the greater availability of treatments for acute ischaemic stroke, including advances in endovascular therapy, personalised assessment of patients before treatment is more important than ever. Women have a higher lifetime risk of stroke; therefore, reducing potential sex differences in the acute stroke setting is crucial for the provision of equitable and fa...
Source: The Lancet Neurology - June 16, 2018 Category: Neurology Source Type: research
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
Publication date: Available online 28 September 2018Source: The Lancet NeurologyAuthor(s): Scott E Kasner, Balakumar Swaminathan, Pablo Lavados, Mukul Sharma, Keith Muir, Roland Veltkamp, Sebastian F Ameriso, Matthias Endres, Helmi Lutsep, Steven R Messé, J David Spence, Krassen Nedeltechev, Kanjana Perera, Gustavo Santo, Veronica Olavarria, Arne Lindgren, Shrikant Bangdiwala, Ashkan Shoamanesh, Scott D Berkowitz, Hardi MundlSummaryBackgroundPatent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurren...
Source: The Lancet Neurology - October 5, 2018 Category: Neurology Source Type: research
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study
This study is registered with ClinicalTrials.gov, number NCT01472926. Findings Between Jan 1, 2012, and Sept 7, 2013, 355 patients were screened, of whom 157 were eligible for intravenous thrombolysis, and 104 patients were enrolled. 52 were assigned to the alteplase group and 52 to tenecteplase. Of 71 patients (35 assigned tenecteplase and 36 assigned alteplase) contributing to the primary endpoint, no significant differences were noted for percentage of penumbral salvaged (68% [SD 28] for the tenecteplase group vs 68% [23] for the alteplase group; mean difference 1·3% [95% CI −9·6 to 12·1]; p=0·81). Neither incide...
Source: The Lancet Neurology - February 26, 2015 Category: Neurology Source Type: research
Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study
Publication date: Available online 27 July 2015 Source:The Lancet Neurology Author(s): Linxin Li, Gabriel S Yiin, Olivia C Geraghty, Ursula G Schulz, Wilhelm Kuker, Ziyah Mehta, Peter M Rothwell Background A third of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, cryptogenic), potentially undermining secondary prevention. If these events are due to occult atheroma, the risk-factor profile and coronary prognosis should resemble that of overt large artery events. If they have a cardioembolic cause, the risk of future cardioembolic events should be increased. We aimed to asses...
Source: The Lancet Neurology - July 28, 2015 Category: Neurology Source Type: research
Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study
Publication date: February 2018 Source:The Lancet Neurology, Volume 17, Issue 2 Author(s): Marian Galovic, Nico Döhler, Barbara Erdélyi-Canavese, Ansgar Felbecker, Philip Siebel, Julian Conrad, Stefan Evers, Michael Winklehner, Tim J von Oertzen, Hans-Peter Haring, Anna Serafini, Giorgia Gregoraci, Mariarosaria Valente, Francesco Janes, Gian Luigi Gigli, Mark R Keezer, John S Duncan, Josemir W Sander, Matthias J Koepp, Barbara Tettenborn Background Stroke is one of the leading causes of acquired epilepsy in adults. An instrument to predict whether people are at high risk of developing post-stroke seizures is not availab...
Source: The Lancet Neurology - January 18, 2018 Category: Neurology Source Type: research
Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial
This report presents a secondary analysis, and follow-up is complete. Findings Between May, 2001, and October, 2008, 1713 patients were enrolled and randomly allocated treatment (855 were assigned stenting and 858 endarterectomy), of whom 1530 individuals were followed up with ultrasound (737 assigned stenting and 793 endarterectomy) for a median of 4·0 years (IQR 2·3–5·0). At least moderate restenosis (≥50%) occurred in 274 patients after stenting (cumulative 5-year risk 40·7%) and in 217 after endarterectomy (29·6%; unadjusted hazard ratio [HR] 1·43, 95% CI 1·21–1·72; p<0·0001). Patients with at lea...
Source: The Lancet Neurology - June 1, 2018 Category: Neurology Source Type: research
Epidemiology, aetiology, and management of ischaemic stroke in young adults
Publication date: September 2018Source: The Lancet Neurology, Volume 17, Issue 9Author(s): Merel S Ekker, Esther M Boot, Aneesh B Singhal, Kay Sin Tan, Stephanie Debette, Anil M Tuladhar, Frank-Erik de LeeuwSummaryEpidemiological evidence suggests that the incidence of ischaemic stroke in young adults (18–50 years) has increased substantially. These patients have a long life expectancy after stroke, and the costs of long-term care pose huge challenges to health-care systems. Although the current recommendations for treatment of young and old (>50 years) patients with stroke are similar, the optimal management of young ad...
Source: The Lancet Neurology - August 15, 2018 Category: Neurology Source Type: research
Priorities to reduce the burden of stroke in Latin American countries
Discussions were focused on the regional and country-specific activities associated with stroke prevention and treatment, including public stroke awareness, prevention strategies, delivery and organisation of care, clinical practice gaps, and unmet needs. The meeting culminated with the adoption of the special Gramado Declaration, signed by all Ministerial officials who attended the meeting. With agreed priorities for stroke prevention, treatment, and research, an opportunity now exists to translate this Declaration into an action plan to reduce the burden of stroke.
Source: The Lancet Neurology - April 26, 2019 Category: Neurology Source Type: research
Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial
Publication date: June 2019Source: The Lancet Neurology, Volume 18, Issue 6Author(s): Gary A Ford, Bipin B Bhakta, Alastair Cozens, Suzanne Hartley, Ivana Holloway, David Meads, John Pearn, Sharon Ruddock, Catherine M Sackley, Eirini-Christina Saloniki, Gillian Santorelli, Marion F Walker, Amanda J FarrinSummaryBackgroundDopamine is a key modulator of striatal function and learning and might improve motor recovery after stroke. Previous small trials of dopamine agonists after stroke provide equivocal evidence of effectiveness on improving motor recovery. We aimed to assess the safety and efficacy of co-careldopa plus routi...
Source: The Lancet Neurology - May 22, 2019 Category: Neurology Source Type: research
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
Publication date: March 2020Source: The Lancet Neurology, Volume 19, Issue 3Author(s): Hugues Chabriat, Claudio L Bassetti, Ute Marx, Marie-Laure Audoli-Inthavong, Aurore Sors, Estelle Lambert, Marine Wattez, Dirk M Hermann, Katharina ALTHAUS, Sergi AMARO, Hee-Joon BAE, Zbigniew BAK, Leonardo BARBARINI, Pietro BASSI, Rodrigo BAZAN, Daniel BERECZKI, Tomasz BERKOWICZ, Joerg BERROUSCHOT, Dylan BLACQUIERE, Waldemar BROLASummaryBackgroundS44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex. S44819 improved stroke recovery in rodents and increased cortical excitabi...
Source: The Lancet Neurology - February 19, 2020 Category: Neurology Source Type: research
